SAGE Therapeutics (NASDAQ:SAGE) had its price target decreased by equities researchers at SunTrust Banks from $50.00 to $40.00 in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. SunTrust Banks’ price objective indicates a potential upside of 27.67% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Wedbush reduced their target price on SAGE Therapeutics from $203.00 to $90.00 and set an “outperform” rating for the company in a research report on Thursday, December 5th. ValuEngine upgraded SAGE Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 5th. Oppenheimer cut their price objective on SAGE Therapeutics from to in a report on Thursday, March 19th. Bank of America upped their price objective on SAGE Therapeutics from to in a report on Tuesday, January 7th. Finally, Mizuho reiterated a “hold” rating and issued a $58.00 price objective on shares of SAGE Therapeutics in a report on Wednesday, March 11th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. SAGE Therapeutics has a consensus rating of “Buy” and a consensus price target of $100.05.

SAGE Therapeutics stock traded up $1.00 during midday trading on Thursday, hitting $31.33. 14,963 shares of the company’s stock were exchanged, compared to its average volume of 1,579,096. SAGE Therapeutics has a 52-week low of $25.01 and a 52-week high of $193.56. The stock has a 50-day moving average price of $52.19 and a two-hundred day moving average price of $100.15. The company has a debt-to-equity ratio of 0.03, a quick ratio of 9.23 and a current ratio of 9.23. The company has a market cap of $1.57 billion, a P/E ratio of -2.39 and a beta of 2.60.

SAGE Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($3.25) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.37. SAGE Therapeutics had a negative return on equity of 59.83% and a negative net margin of 9,904.45%. The business had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $3.76 million. During the same period in the previous year, the business earned ($3.38) earnings per share. The firm’s revenue was up 617.9% on a year-over-year basis. As a group, sell-side analysts expect that SAGE Therapeutics will post -12.96 earnings per share for the current year.

Large investors have recently made changes to their positions in the company. Verus Capital Partners LLC purchased a new position in shares of SAGE Therapeutics during the fourth quarter valued at about $25,000. Ladenburg Thalmann Financial Services Inc. grew its position in shares of SAGE Therapeutics by 40.2% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 771 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 221 shares in the last quarter. Tobam grew its position in shares of SAGE Therapeutics by 50.0% during the fourth quarter. Tobam now owns 900 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 300 shares in the last quarter. Altshuler Shaham Ltd grew its position in shares of SAGE Therapeutics by 17.2% during the fourth quarter. Altshuler Shaham Ltd now owns 1,363 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 200 shares in the last quarter. Finally, Point72 Hong Kong Ltd grew its position in SAGE Therapeutics by 33.3% in the fourth quarter. Point72 Hong Kong Ltd now owns 1,400 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 350 shares in the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

See Also: SEC Filing

The Fly

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.